Silvia Radwanski Stuart
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Silvia Radwanski Stuart has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Heloisa A. Carvalho
Radiotherapy, Instituto de Radiologia, Universidade de São Paulo, Sao Paulo, Brazil
2 shared publications- Heloisa de Andrade Carvalho
Departamento de Radiologia E Oncologia, Divisao de Radioterapia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil
2 shared publications Alexandre Mendonça Munhoz
Instituto de Radiologia (INRAD) — Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
1 shared publication- André Luis Pereira de Albuquerque
Divisão de Pneumologia, Instituto do Coração - InCor - Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil
1 shared publication - Bruna Salani Mota
Instituto do Câncer do Estado de São Paulo, Sao Paulo, SP, Brazil
1 shared publication - Bruno Salvador Sobreira Lima
Department of Mastology, Division of Gynecology and Obstetrics, Faculty of Medicine of University of São Paulo, University of São Paulo, Sao Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 16 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Impact of COVID-19 on breast cancer care - a retrospective cohort study in Brazil
Background: The COVID-19 pandemic disrupted healthcare systems worldwide and substantially affected breast cancer care. International reports have described delays in diagnosis, stage, and modifications in treatment strategies, however, little is known about how the pandemic has affected the entire sequence of steps from diagnosis to treatment initiation and completion within the Brazilian public healthcare system. Methods: This retrospective cohort study followed the STROBE guidelines and was conducted at a high-volume public cancer center in São Paulo, Brazil. A total of 1,306 women diagnosed with invasive or in situ breast cancer were included: 755 patients in the prepandemic period (March 2018–February 2019) and 551 patients in the pandemic period (March 2020–February 2021). Clinical, pathological, treatment, and time-related variables along the care pathway were extracted from electronic medical records and compared using appropriate statistical tests, with significance set at p < 0.05. Results: A 32% reduction in the number of treated patients occurred during the pandemic (551 vs. 755). Patients who were diagnosed during the pandemic were younger (48.3 vs. 53.6 years; p < 0.001) and presented with more advanced clinical stages, including higher rates of cT3–T4 tumors and nodal involvement ( p < 0.001). The use of neoadjuvant therapy increased from 36.8% to 49%, particularly among early-stage and luminal B tumors. Key intervals across the care pathway were significantly prolonged, including time to initial treatment and completion of adjuvant therapy. Radiotherapy practices have shifted toward hypofractionated protocols. Conclusion: The first year of the COVID-19 pandemic was associated with fewer treated patients, stage migration toward more advanced disease, greater reliance on neoadjuvant therapy, and prolonged time intervals along the care pathway from diagnosis to treatment initiation and completion. These findings highlight the need for resilient oncology systems, protected treatment pathways, and strengthened care coordination to mitigate the impact of future healthcare crises.
- 16 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessImpact of COVID-19 on breast cancer care - a retrospective cohort study in Brazil
Background: The COVID-19 pandemic disrupted healthcare systems worldwide and substantially affected breast cancer care. International reports have described delays in diagnosis, stage, and modifications in treatment strategies, however, little is known about how the pandemic has affected the entire sequence of steps from diagnosis to treatment initiation and completion within the Brazilian public healthcare system. Methods: This retrospective cohort study followed the STROBE guidelines and was conducted at a high-volume public cancer center in São Paulo, Brazil. A total of 1,306 women diagnosed with invasive or in situ breast cancer were included: 755 patients in the prepandemic period (March 2018–February 2019) and 551 patients in the pandemic period (March 2020–February 2021). Clinical, pathological, treatment, and time-related variables along the care pathway were extracted from electronic medical records and compared using appropriate statistical tests, with significance set at p < 0.05. Results: A 32% reduction in the number of treated patients occurred during the pandemic (551 vs. 755). Patients who were diagnosed during the pandemic were younger (48.3 vs. 53.6 years; p < 0.001) and presented with more advanced clinical stages, including higher rates of cT3–T4 tumors and nodal involvement ( p < 0.001). The use of neoadjuvant therapy increased from 36.8% to 49%, particularly among early-stage and luminal B tumors. Key intervals across the care pathway were significantly prolonged, including time to initial treatment and completion of adjuvant therapy. Radiotherapy practices have shifted toward hypofractionated protocols. Conclusion: The first year of the COVID-19 pandemic was associated with fewer treated patients, stage migration toward more advanced disease, greater reliance on neoadjuvant therapy, and prolonged time intervals along the care pathway from diagnosis to treatment initiation and completion. These findings highlight the need for resilient oncology systems, protected treatment pathways, and strengthened care coordination to mitigate the impact of future healthcare crises.
- Open Access
- 20 December 2025
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 31 (1) , 107-123
Concurrent systemic treatment during stereotactic radiosurgery for breast cancer brain metastasis: analysis of survival outcomes and propensity score matching analysis
Background: Stereotactic radiosurgery (SRS) has a fundamental role in the treatment of breast cancer brain metastases (BCBM). Current data on the matter comes from trials with brain metastases from any histology or with limited description on survival, focusing mostly on response rate. This retrospective study will assess the impact of SRS on survival and its interaction with systemic treatment (ST). Materials and methods: Charts from January 2011 to July 2022 were retrospectively assessed to investigate the relation between SRS and concurrent ST for BCBM. Since different protocols for ST can be offered, we divided our cohort and assessed the impact of different concurrent ST, in each subtype, on oncological survival outcomes. Results: There were 208 patients, 138 met inclusion criteria. Median follow-up was 10.7 months. Median overall survival (OS), progression-free survival (PFS), survival-free from CNS progression and survival-free from new neurological deficits were 12.5, 14.1, 16.2, and 16.3 months, respectively. For the whole cohort, any concurrent ST did not impact OS (p = 0.68). For hormone-positive patients, concurrent hormone therapy (HT) did not impact OS (p = 0.75). For those receiving anti-human epidermal growth factor receptor-type 2 (anti-HER-2) therapy there was no impact on OS (p = 0.47). Propensity score match analysis found that ST during SRS would reduce the chance of death by 19.4%. ST did not impact toxicities, chances of radionecrosis nor survival free of neurological symptoms. Conclusion: There has been an increase in research on the synergy between SRS and ST. In our study, this synergy was not sensible for oncological outcomes. New prospective research should focus more on survival outcomes than response rate. Keywords: stereotactic radiosurgery breast cancer brain metastasis
- 20 December 2025
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 31 (1) , 107-123
Open AccessConcurrent systemic treatment during stereotactic radiosurgery for breast cancer brain metastasis: analysis of survival outcomes and propensity score matching analysis
Background: Stereotactic radiosurgery (SRS) has a fundamental role in the treatment of breast cancer brain metastases (BCBM). Current data on the matter comes from trials with brain metastases from any histology or with limited description on survival, focusing mostly on response rate. This retrospective study will assess the impact of SRS on survival and its interaction with systemic treatment (ST). Materials and methods: Charts from January 2011 to July 2022 were retrospectively assessed to investigate the relation between SRS and concurrent ST for BCBM. Since different protocols for ST can be offered, we divided our cohort and assessed the impact of different concurrent ST, in each subtype, on oncological survival outcomes. Results: There were 208 patients, 138 met inclusion criteria. Median follow-up was 10.7 months. Median overall survival (OS), progression-free survival (PFS), survival-free from CNS progression and survival-free from new neurological deficits were 12.5, 14.1, 16.2, and 16.3 months, respectively. For the whole cohort, any concurrent ST did not impact OS (p = 0.68). For hormone-positive patients, concurrent hormone therapy (HT) did not impact OS (p = 0.75). For those receiving anti-human epidermal growth factor receptor-type 2 (anti-HER-2) therapy there was no impact on OS (p = 0.47). Propensity score match analysis found that ST during SRS would reduce the chance of death by 19.4%. ST did not impact toxicities, chances of radionecrosis nor survival free of neurological symptoms. Conclusion: There has been an increase in research on the synergy between SRS and ST. In our study, this synergy was not sensible for oncological outcomes. New prospective research should focus more on survival outcomes than response rate. Keywords: stereotactic radiosurgery breast cancer brain metastasis
- Open Access
- 10 August 2023
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 28 (5) , 582-591
Can we predict who will benefit from the deep inspiration breath hold (DIBH) technique for breast cancer irradiation?
Background: The objective was to explore the clinical use of an “in-house” prototype developed to monitor respiratory motion to implement the deep inspiration breath hold technique (DIBH), compare dosimetric differences, and assess whether simple anatomic metrics measured on free breathing (FB) computed tomography scan (CT) can help in selecting patients that would benefit the most from the technique. Materials and methods: A prospective study was conducted on patients with left breast cancer with an indication of adjuvant radiotherapy for breast only. Treatment simulation consisted of four series of CTs: the first during FB and three in DIBH to assess the reproducibility and stability of apnea. Contouring was based on the RTOG atlas, and planning was done in both FB and DIBH. Dosimetric and geometric parameters were assessed and compared between FB and DIBH. Results: From June 2020 to December 2021, 30 patients with left breast cancer were recruited. Overall, the DIBH technique presented a mean dose reduction of 24% in the heart and 30% in the left anterior descendent coronary artery (LAD) (p < 0.05). The only geometric parameter correlated to a 30% dose reduction in the mean heart dose and LAD doses was the anterolateral distance from the heart to the chest wall of at least 1.5 cm measured on FB (p < 0.0001). Conclusion: The prototype enabled the use of the DIBH technique with dose reductions in the heart and LAD. The benefit of the DIBH technique can be predicted on FB CT by measuring the distance between the heart and chest wall at the treatment isocenter. Background: The objective was to explore the clinical use of an “in-house” prototype developed to monitor respiratory motion to implement the deep inspiration breath hold technique (DIBH), compare dosimetric differences, and assess whether simple anatomic metrics measured on free breathing (FB) computed tomography scan (CT) can help in selecting patients that would benefit the most from the technique. Materials and methods: A prospective study was conducted on patients with left breast cancer with an indication of adjuvant radiotherapy for breast only. Treatment simulation consisted of four series of CTs: the first during FB and three in DIBH to assess the reproducibility and stability of apnea. Contouring was based on the RTOG atlas, and planning was done in both FB and DIBH. Dosimetric and geometric parameters were assessed and compared between FB and DIBH. Results: From June 2020 to December 2021, 30 patients with left breast cancer were recruited. Overall, the DIBH technique presented a mean dose reduction of 24% in the heart and 30% in the left anterior descendent coronary artery (LAD) (p < 0.05). The only geometric parameter correlated to a 30% dose reduction in the mean heart dose and LAD doses was the anterolateral distance from the heart to the chest wall of at least 1.5 cm measured on FB (p < 0.0001). Conclusion: The prototype enabled the use of the DIBH technique with dose reductions in the heart and LAD. The benefit of the DIBH technique can be predicted on FB CT by measuring the distance between the heart and chest wall at the treatment isocenter.
- 10 August 2023
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 28 (5) , 582-591
Open AccessCan we predict who will benefit from the deep inspiration breath hold (DIBH) technique for breast cancer irradiation?
Background: The objective was to explore the clinical use of an “in-house” prototype developed to monitor respiratory motion to implement the deep inspiration breath hold technique (DIBH), compare dosimetric differences, and assess whether simple anatomic metrics measured on free breathing (FB) computed tomography scan (CT) can help in selecting patients that would benefit the most from the technique. Materials and methods: A prospective study was conducted on patients with left breast cancer with an indication of adjuvant radiotherapy for breast only. Treatment simulation consisted of four series of CTs: the first during FB and three in DIBH to assess the reproducibility and stability of apnea. Contouring was based on the RTOG atlas, and planning was done in both FB and DIBH. Dosimetric and geometric parameters were assessed and compared between FB and DIBH. Results: From June 2020 to December 2021, 30 patients with left breast cancer were recruited. Overall, the DIBH technique presented a mean dose reduction of 24% in the heart and 30% in the left anterior descendent coronary artery (LAD) (p < 0.05). The only geometric parameter correlated to a 30% dose reduction in the mean heart dose and LAD doses was the anterolateral distance from the heart to the chest wall of at least 1.5 cm measured on FB (p < 0.0001). Conclusion: The prototype enabled the use of the DIBH technique with dose reductions in the heart and LAD. The benefit of the DIBH technique can be predicted on FB CT by measuring the distance between the heart and chest wall at the treatment isocenter. Background: The objective was to explore the clinical use of an “in-house” prototype developed to monitor respiratory motion to implement the deep inspiration breath hold technique (DIBH), compare dosimetric differences, and assess whether simple anatomic metrics measured on free breathing (FB) computed tomography scan (CT) can help in selecting patients that would benefit the most from the technique. Materials and methods: A prospective study was conducted on patients with left breast cancer with an indication of adjuvant radiotherapy for breast only. Treatment simulation consisted of four series of CTs: the first during FB and three in DIBH to assess the reproducibility and stability of apnea. Contouring was based on the RTOG atlas, and planning was done in both FB and DIBH. Dosimetric and geometric parameters were assessed and compared between FB and DIBH. Results: From June 2020 to December 2021, 30 patients with left breast cancer were recruited. Overall, the DIBH technique presented a mean dose reduction of 24% in the heart and 30% in the left anterior descendent coronary artery (LAD) (p < 0.05). The only geometric parameter correlated to a 30% dose reduction in the mean heart dose and LAD doses was the anterolateral distance from the heart to the chest wall of at least 1.5 cm measured on FB (p < 0.0001). Conclusion: The prototype enabled the use of the DIBH technique with dose reductions in the heart and LAD. The benefit of the DIBH technique can be predicted on FB CT by measuring the distance between the heart and chest wall at the treatment isocenter.
- Open Access
- 1 January 2021
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 26 (5) , 730-739
Complications after breast reconstruction with alloplastic material in breast cancer patients submitted or not to post mastectomy radiotherapy
Background and purpose: Breast reconstruction following mastectomy is a relevant element of breast cancer treatment. The purpose of this study was to evaluate the influence of radiotherapy (RT) on local complications in patients with breast cancer that had undergone breast reconstruction with alloplastic material. Materials and methods: Retrospective study of breast cancer patients submitted to mastectomy and breast reconstruction from 2009 to 2013. Clinical and treatment variables were correlated with early and late complications. Results: 251 patients were included; mean age was 49.7 (25 to 78) years. Reconstruction was immediate in 94% of the patients, with 88% performed with a temporary tissue expander. Postoperative radiotherapy (RT) was delivered to 167 patients (66.5%). Early complications were present in 26.3% of the patients. Irradiated patients presented 5.4% incidence of late complications versus 2.4% for non-irradiated patients (p = 0.327). Diabetes (OR = 3.41 95% CI: 1.23-9.45, p = 0.018) and high body mass index (BMI) (OR = 2.65; 95% CI: 1.60-4.37, p < 0.0001) were the main risk factors. The overall incidence of late complications was 4.4%, with predominance of severe capsular contracture (8/11). Arterial hypertension (OR = 4.78; 95% CI: 1.97-11.63, p = 0.001), BMI (OR = 0.170; 95% CI: 0.048-0.607, p = 0.006) and implant placement (OR = 3.55; 95% CI: 1.26-9.99, p = 0.016) were related to late complications. Conclusions: The overall rate of complications was low in this population. Radiotherapy delivery translated into a higher but not statistically significant risk of late complications when compared with the non-irradiated patients. Already well-known clinical risk factors for complications after breast reconstruction were identified.
- 1 January 2021
- Published by VM Media Group sp. z o.o in Reports of Practical Oncology and Radiotherapy
- Vol. 26 (5) , 730-739
Open AccessComplications after breast reconstruction with alloplastic material in breast cancer patients submitted or not to post mastectomy radiotherapy
Background and purpose: Breast reconstruction following mastectomy is a relevant element of breast cancer treatment. The purpose of this study was to evaluate the influence of radiotherapy (RT) on local complications in patients with breast cancer that had undergone breast reconstruction with alloplastic material. Materials and methods: Retrospective study of breast cancer patients submitted to mastectomy and breast reconstruction from 2009 to 2013. Clinical and treatment variables were correlated with early and late complications. Results: 251 patients were included; mean age was 49.7 (25 to 78) years. Reconstruction was immediate in 94% of the patients, with 88% performed with a temporary tissue expander. Postoperative radiotherapy (RT) was delivered to 167 patients (66.5%). Early complications were present in 26.3% of the patients. Irradiated patients presented 5.4% incidence of late complications versus 2.4% for non-irradiated patients (p = 0.327). Diabetes (OR = 3.41 95% CI: 1.23-9.45, p = 0.018) and high body mass index (BMI) (OR = 2.65; 95% CI: 1.60-4.37, p < 0.0001) were the main risk factors. The overall incidence of late complications was 4.4%, with predominance of severe capsular contracture (8/11). Arterial hypertension (OR = 4.78; 95% CI: 1.97-11.63, p = 0.001), BMI (OR = 0.170; 95% CI: 0.048-0.607, p = 0.006) and implant placement (OR = 3.55; 95% CI: 1.26-9.99, p = 0.016) were related to late complications. Conclusions: The overall rate of complications was low in this population. Radiotherapy delivery translated into a higher but not statistically significant risk of late complications when compared with the non-irradiated patients. Already well-known clinical risk factors for complications after breast reconstruction were identified.
- Open Access
- 1 December 2018
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 44 (6) , 469-476
Impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer
Objective: To evaluate the impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer. Methods: Breast cancer patients in whom thoracic radiotherapy was indicated after surgical treatment and chemotherapy were submitted to HRCT, respiratory evaluation, and exercise capacity evaluation before radiotherapy and at three months after treatment completion. Respiratory muscle strength testing, measurement of chest wall mobility, and complete pulmonary function testing were performed for respiratory evaluation; cardiopulmonary exercise testing was performed to evaluate exercise capacity. The total radiotherapy dose was 50.4 Gy (1.8 Gy/fraction) to the breast or chest wall, including supraclavicular lymph nodes (SCLN) or not. Dose-volume histograms were calculated for each patient with special attention to the ipsilateral lung volume receiving 25 Gy (V25), in absolute and relative values, and mean lung dose. Results: The study comprised 37 patients. After radiotherapy, significant decreases were observed in respiratory muscle strength, chest wall mobility, exercise capacity, and pulmonary function test results (p < 0.05). DLCO was unchanged. HRCT showed changes related to radiotherapy in 87% of the patients, which was more evident in the patients submitted to SCLN irradiation. V25% significantly correlated with radiation pneumonitis. Conclusions: In our sample of patients with breast cancer, thoracic radiotherapy seemed to have caused significant losses in respiratory and exercise capacity, probably due to chest wall restriction; SCLN irradiation represented an additional risk factor for the development of radiation pneumonitis.
- 1 December 2018
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 44 (6) , 469-476
Open AccessImpact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer
Objective: To evaluate the impact of thoracic radiotherapy on respiratory function and exercise capacity in patients with breast cancer. Methods: Breast cancer patients in whom thoracic radiotherapy was indicated after surgical treatment and chemotherapy were submitted to HRCT, respiratory evaluation, and exercise capacity evaluation before radiotherapy and at three months after treatment completion. Respiratory muscle strength testing, measurement of chest wall mobility, and complete pulmonary function testing were performed for respiratory evaluation; cardiopulmonary exercise testing was performed to evaluate exercise capacity. The total radiotherapy dose was 50.4 Gy (1.8 Gy/fraction) to the breast or chest wall, including supraclavicular lymph nodes (SCLN) or not. Dose-volume histograms were calculated for each patient with special attention to the ipsilateral lung volume receiving 25 Gy (V25), in absolute and relative values, and mean lung dose. Results: The study comprised 37 patients. After radiotherapy, significant decreases were observed in respiratory muscle strength, chest wall mobility, exercise capacity, and pulmonary function test results (p < 0.05). DLCO was unchanged. HRCT showed changes related to radiotherapy in 87% of the patients, which was more evident in the patients submitted to SCLN irradiation. V25% significantly correlated with radiation pneumonitis. Conclusions: In our sample of patients with breast cancer, thoracic radiotherapy seemed to have caused significant losses in respiratory and exercise capacity, probably due to chest wall restriction; SCLN irradiation represented an additional risk factor for the development of radiation pneumonitis.